甘李药业
(603087)
| 流通市值：258.35亿 | | | 总市值：280.34亿 |
| 流通股本：5.54亿 | | | 总股本：6.01亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,500,170,909.85 | 3,076,618,971.99 | 2,552,990,893.78 | 2,442,708,603.2 |
| 应收票据及应收账款 | 260,952,578.28 | 371,005,522.18 | 269,599,231.21 | 383,735,270.9 |
| 应收账款 | 260,952,578.28 | 371,005,522.18 | 269,599,231.21 | 383,735,270.9 |
| 应收款项融资 | 10,440,234.86 | 6,312,425.46 | 18,561,967.25 | 1,634,782.89 |
| 预付款项 | 65,038,178.77 | 77,369,836.05 | 59,366,039.72 | 40,979,491.54 |
| 其他应收款合计 | 4,067,790.39 | 14,858,181.49 | 3,602,947.45 | 3,491,907.62 |
| 应收股利 | - | 10,383,444 | - | - |
| 存货 | 1,028,209,422.59 | 950,337,986.09 | 932,042,171.36 | 860,506,306.14 |
| 其他流动资产 | 52,855,270.58 | 41,691,546.46 | 31,883,590.65 | 32,263,551.43 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,488,421,495.55 | 6,330,733,352.24 | 6,215,027,747.41 | 6,175,749,710.54 |
| 非流动资产: | | | | |
| 债权投资 | 493,279,827.63 | 409,663,888.89 | 307,122,916.67 | 304,658,333.33 |
| 其他非流动金融资产 | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 |
| 固定资产 | 2,583,228,479.48 | 2,342,820,848.74 | 1,851,745,745.49 | 1,872,067,763.13 |
| 在建工程 | 1,287,823,201.59 | 1,516,829,114.72 | 2,024,005,518.27 | 2,006,961,148.27 |
| 使用权资产 | 4,571,212.05 | 4,561,198.02 | 4,475,734.51 | 6,592,364.52 |
| 无形资产 | 273,217,267.63 | 275,364,776.74 | 271,278,567.88 | 278,082,595.92 |
| 开发支出 | 831,881,020.7 | 823,383,539.85 | 818,633,186.96 | 813,105,292.99 |
| 长期待摊费用 | 7,541,098.04 | 7,984,713.53 | 8,426,265.99 | 8,868,054.7 |
| 递延所得税资产 | 165,060,138.61 | 157,012,778.79 | 152,239,174.14 | 168,953,020.84 |
| 其他非流动资产 | 56,596,924.26 | 54,203,196.18 | 36,999,556.26 | 49,985,187.56 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 5,733,199,169.99 | 5,621,824,055.46 | 5,504,926,666.17 | 5,539,273,761.26 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 12,221,620,665.54 | 11,952,557,407.7 | 11,719,954,413.58 | 11,715,023,471.8 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 111,039,231.91 | 96,322,808.19 | 107,433,009.23 | 105,541,739.99 |
| 应付账款 | 111,039,231.91 | 96,322,808.19 | 107,433,009.23 | 105,541,739.99 |
| 合同负债 | 52,257,417.95 | 30,869,944.63 | 32,639,152.15 | 52,991,852.39 |
| 应付职工薪酬 | 167,505,096.69 | 127,505,392 | 151,941,854.52 | 139,761,214.89 |
| 应交税费 | 18,813,663.8 | 14,660,929.72 | 10,206,577.59 | 16,910,777.27 |
| 其他应付款合计 | 454,180,202.82 | 491,614,050.22 | 377,540,224.77 | 454,009,437.8 |
| 应付股利 | 1,965,508 | 18,829,363.6 | - | - |
| 一年内到期的非流动负债 | 2,361,167.58 | 2,370,318.27 | 2,292,334.37 | 3,958,443.73 |
| 其他流动负债 | 517,838.22 | 368,708.01 | 297,868.18 | 275,580.81 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 806,674,618.97 | 763,712,151.04 | 682,351,020.81 | 773,449,046.88 |
| 非流动负债: | | | | |
| 租赁负债 | 3,672,433.54 | 3,782,154.3 | 3,909,110.41 | 5,447,249.65 |
| 长期应付款 | 11,420,438.19 | 13,654,272.82 | 13,778,661.53 | 13,995,107.23 |
| 递延收益 | 171,126,795.22 | 175,023,822.96 | 177,324,731.68 | 179,625,640.4 |
| 递延所得税负债 | 21,862,044.76 | 19,295,755.21 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 208,081,711.71 | 211,756,005.29 | 195,012,503.62 | 199,067,997.28 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,014,756,330.68 | 975,468,156.33 | 877,363,524.43 | 972,517,044.16 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 601,065,290 | 601,201,750 | 594,161,750 | 594,161,750 |
| 资本公积 | 3,551,504,399.45 | 3,516,467,281.42 | 3,354,945,052.71 | 3,350,753,839.87 |
| 减:库存股 | 200,846,739.31 | 188,087,492 | 71,364,020 | 71,364,020 |
| 其他综合收益 | 2,952,172.83 | 3,679,292.13 | 3,706,443.79 | 3,817,428.85 |
| 盈余公积 | 300,532,645 | 297,080,875 | 297,080,875 | 297,080,875 |
| 未分配利润 | 6,951,656,566.89 | 6,746,747,186.27 | 6,664,060,427.4 | 6,568,056,149.2 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 11,206,864,334.86 | 10,977,088,892.82 | 10,842,590,528.9 | 10,742,506,022.92 |
| 少数股东权益 | - | 358.55 | 360.25 | 404.72 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 11,206,864,334.86 | 10,977,089,251.37 | 10,842,590,889.15 | 10,742,506,427.64 |
| 负债和股东权益合计 | 12,221,620,665.54 | 11,952,557,407.7 | 11,719,954,413.58 | 11,715,023,471.8 |
| 公告日期 | 2024-10-23 | 2024-08-29 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |